Development and internal validation of a prognostic nomogram incorporating F-NLR and HAGR scores in patients with oral squamous cell carcinoma: a single-center retrospective cohort study - Summary - MDSpire
Advertisement
Development and internal validation of a prognostic nomogram incorporating F-NLR and HAGR scores in patients with oral squamous cell carcinoma: a single-center retrospective cohort study
To construct a novel individualized prognostic model for patients with oral squamous cell carcinoma (OSCC) by integrating traditional clinical parameters with F-NLR and HAGR scores, addressing the limitations of the TNM staging system.
Approach:
Study Design: Retrospective analysis of clinical data from 292 OSCC patients who underwent radical surgical resection.
Data Analysis: Determined optimal cut-off values using the Youden index from ROC curves; performed univariate and multivariate Cox regression analyses.
Nomogram Construction: Developed a nomogram predicting 1-, 3-, and 5-year cancer-specific survival (CSS) rates based on identified independent prognostic factors.
Validation: Conducted internal validation of the nomogram; external validation was not performed.
Key Findings:
119 cancer-related deaths observed during a median follow-up of 41 months.
Independent prognostic factors identified: age, history of precancerous lesions, N classification, postoperative adjuvant therapy, F-NLR, and HAGR scores.
Nomogram C-index of 0.73; AUC for predicting 1-, 3-, and 5-year CSS were 0.798, 0.754, and 0.836, respectively, indicating acceptable model discrimination.
Calibration plots showed high consistency between predicted probabilities and actual survival observations.
Interpretation:
The nomogram demonstrates acceptable predictive accuracy for individualized risk stratification in OSCC patients.
Limitations:
Internal validation only; external validation in multi-center cohorts is required.
Conducted at a single center, which may limit generalizability.
Conclusion:
The proposed nomogram integrating F-NLR and HAGR scores with clinical parameters requires further validation before it can be recommended for routine clinical use.